


California Department of Public Health Immunization Updates for Providers

Friday, November 3, 2023

9:00AM – 10:30AM

Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be
dropped into, “Chat”



Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the

[CDPH Weekly Immunization Updates for Providers](#)



To be added to the CDPH email messaging listserv for providers, please email your request to billiedawn.greenblatt@cdph.ca.gov

If you have post-webinar-related questions, please email leslie.amani@cdph.ca.gov

Agenda: Friday November 3, 2023

No.	Item	Speaker(s)	Time (AM)
1	Welcome and Announcements	Leslie Amani (CDPH)	9:00 – 9:05
2	COVID-19 Vaccine Administration Data	Hailey Maeda (CDPH)	9:05 – 9:10
3	Clinical Update	Caterina Liu, M.D. (CDPH)	9:10 – 9:20
4	Respiratory Syncytial Virus (RSV)	Christina Sapad (CDPH)	9:20 – 9:30
5	Pharmacy and Long-term Care Facilities (LTCF)	Edward Salaguinto, PharmD, RPh (CDPH)	9:30 – 9:35
6	CAIR/RIDE Registry ID and Demonstration	Kelley Leung, RN (CDPH)	9:35 – 9:45
7	CDPH COVID-19 Testing Updates	Stefanie Medlin (CDPH)	9:45 – 9:55
8	Vaccine Management	Josh Pocus (My Turn) and Maria Volk (myCAvax)	9:55 – 10:05
9	Resources and Q&A	Leslie Amani (CDPH)	10:05 – 10:30
Thank you!			

Announcements

Leslie Amani, CDPH




Holidays and Webinar Cancellations

Saturday November 4: Turn your clocks back one hour before heading to bed. Time to “Fall back”. 

Friday, November 10: In observance of Veterans’ Day, there will be no Friday provider webinar



Tuesday, November 14: Due to a CDPH all-staff meeting, there will be no Tuesday LHD webinar. 

Thursday, November 23: Happy Thanksgiving! 

Friday, November 24: There will be no Friday provider webinar the day after Thanksgiving.

Please note that the Provider Call Center will be closed on these same dates.



Vaccines for Adults (VFA) Webinar

When: **Wednesday, November 15, 2023**

Time: 12PM – 1PM, PT

[Register Here!](#)



This webinar will be focused on reviewing this year's VFA program ordering data, VFA Program Updates, updated ACIP adult immunization recommendations and resources. There will also be an opportunity for you to ask VFA-program-related questions during the Q&A session towards the end of the webinar.



Upcoming Crucial Conversations Webinar

Topic: Talking to patients about staying safe from respiratory viruses during the holidays


Description: On November 16th, join us with Sharon Goldfarb, DNP, RN, FNP-BC, for a webinar on how to effectively communicate with patients about staying safe from respiratory viruses during the holiday season.

Speaker: Sharon Goldfarb, DNP, RN, FNP-BC

When: Wednesday, November 16, 2023

Time: 12PM - 1PM, PT

Please register [here](#)





Vacunas Otoño-Invierno 2023

FALL-WINTER 2023-24 IMMUNIZATIONS

	Who is eligible?	What Immunizations are recommended?	When should I get it?
Influenza 	6 months and older	<u>Flu vaccines</u> target 4 strains of flu and are available as a shot or nasal spray. Flu vaccine prevents millions of illnesses and flu-related doctor's visits each year.	September or October are ideal, but catching up later can still help.
COVID-19 	6 months and older	<u>Updated COVID-19 vaccines</u> target the Omicron XBB strain to protect against COVID-19 this fall and winter	Get it now to help protect against severe disease (if at least two months since your last COVID-19 shot).
RSV (Pregnant Persons) 	Pregnant persons during weeks 32-36 of pregnancy	<u>RSV vaccine</u> to reduce the risk of severe RSV disease in infants (baby will receive protection that lasts for months after birth)	Recommended from September to January to help protect your baby during RSV season
RSV (Infants and Toddlers) 	All infants from birth to 8 months and children 8-19 months at high risk of severe RSV disease	<u>Immunization</u> contains preventive antibodies that help fight RSV infections and protect children from getting very sick.	Before or during RSV season, usually October-March
RSV (Older Adults) 	60 years and older	<u>RSV vaccine</u> to protect older adults against RSV disease	Available now - Talk with your doctor to determine if vaccination is right for you.

OR


Where to get vaccinated?

- Contact your doctor or local pharmacy or visit [MyTurn.ca.gov](https://myturn.ca.gov). Influenza and COVID-19 vaccines continue to be free for most people through their private, Medi-Cal or Medicare insurance plans.
- Check with your insurance on timing of RSV immunization coverage.
- You can receive Influenza, COVID-19 and/or RSV Immunizations during the same visit.
- Adults without health insurance can get no cost COVID-19 vaccine at many pharmacies and clinics participating in the [Bridge Access Program](#). Visit [Vaccines.gov](https://vaccines.gov) to find the nearest location.
- Children who are Medi-Cal eligible, American Indian/Alaskan Native, uninsured and underinsured may get no cost vaccines through the [Vaccines for Children Program](#).

Thanks to Katelyn Jetelina, PhD, MPH and Caitlin Rivers, PhD, MPH for allowing CDPH to adapt this resource.

California Department of Public Health | Immunization Branch IMM-1481 (10/23)

New: Now in Spanish!



VACUNAS OTOÑO-INVIERNO 2023



	¿Quién es elegible?	¿Qué vacunas se recomiendan?	¿Cuándo debería recibirlo?
Influenza 	6 meses y mayor	<u>Las vacunas contra la gripe</u> se dirigen a 4 cepas de gripe y están disponibles en forma de inyección o aerosol nasal. La vacuna contra la gripe previene millones de enfermedades y visitas al médico relacionadas con la gripe cada año.	Septiembre y octubre son ideales, pero más tarde también es bueno, ya que la temporada de gripe puede durar hasta la primavera.
COVID-19 	6 meses y mayor	<u>Las vacunas COVID-19 actualizadas</u> se dirigen a la cepa Omicron XBB para proteger contra el COVID-19 este otoño e invierno	Consígala ahora para ayudar a protegerse contra enfermedades graves (y al menos dos meses después de su última vacuna contra el COVID-19).
VRS (Adultos mayores) 	60 años y mayor	<u>Dos vacunas contra el VRS</u> para proteger a los adultos mayores contra la enfermedad por VRS	Disponible ahora: hable con su médico para determinar si la vacuna es adecuada para usted.
VRS (Personas Embarazadas) 	Personas embarazadas durante las semanas 32-36 de embarazo.	<u>Vacuna contra el VRS</u> para reducir el riesgo de enfermedad grave por VRS en los bebés (la protección se transmitirá al bebé durante los primeros meses de vida)	Recomendado de septiembre a enero para ayudar a proteger a su bebé durante la temporada de VRS
VRS (bebés y niños pequeños) 	Todos los bebés desde el nacimiento hasta los 8 meses y los niños de 8 a 19 meses con alto riesgo de enfermedad grave por VSR	<u>La vacuna</u> contiene anticuerpos preventivos que ayudan a combatir las infecciones por VRS y protegen a los niños de enfermarse gravemente.	Antes o durante la temporada de VRS, generalmente de octubre a marzo


¿Dónde vacunarse?

- Comuníquese con su médico o farmacia local. Las vacunas contra la influenza y el COVID-19 siguen siendo gratuitas para la mayoría de las personas a través de sus planes de seguro médico, Medi-Cal o Medicare.
- Consulte con su seguro médico sobre el momento de la cobertura de la vacuna contra el VRS.
- Puede recibir vacunas contra la influenza, COVID-19 y/o VRS durante la misma visita.
- Los adultos sin seguro médico pueden recibir la vacuna COVID-19 sin costo en muchas farmacias y clínicas que participan en el [Programa Bridge Access](#). Visite vaccines.gov para encontrar la ubicación más cercana.
- Los niños que son elegibles para Medi-Cal, los Indios Americanos/Nativos de Alaska, los que no tienen seguro y los que tienen seguro insuficiente pueden recibir vacunas sin costo a través del [Programa de Vacunas para Niños](#).

Gracias a Katelyn Jetelina, PhD, MPH y Caitlin Rivers, PhD, MPH por permitir que CDPH adapte este recurso.

California Department of Public Health | Immunization Branch IMM-1481 (10/23)

Respiratory Syncytial Virus (RSV) FAQs on EZIZ



ENHANCED BY Google

A one-stop shop for immunization training and resources.

Home

Vaccine Programs

Vaccine Management

Storage Units

Temperature Monitoring

Training & Webinars

Clinic Resources

Patient Resources

Contact VFC

Phone: (877) 243-8832

Hours:

Mon-Thurs, 9AM-4:30PM

Friday, 9AM-4PM

[Send us an email](#)

Fax: (877) 329-9832

▶ VFC Field Representatives

▶ Find VFC providers

▶ Sign up for EZIZ emails

▶ Frequently Asked Questions

RSV-FAQs

RSV FAQs

This webpage is designed to help providers and local health department staff stay abreast on the latest information on RSV immunizations.

What is RSV?

Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes colds, but may cause severe disease in infants and older adults. In the United States, RSV usually starts in the fall season and peaks in the winter.

RSV is the leading cause of hospitalization and the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the United States. Almost all children get RSV at least once before they are two years of age.

In adults, the risk of severe RSV illness also increases with age. Infections are especially dangerous for older adults or those with underlying medical conditions. Each year an estimated 60,000-160,000 older adults are hospitalized and up to 10,000 die due to RSV.

Jump to:

- [Adults](#)
- [Infants](#)
- [Pregnant People](#)

RSV (RESPIRATORY SYNCYTIAL VIRUS)



RSV (Respiratory Syncytial Virus)

Symptom Management & Care

ALERT: There is currently a nationwide supply shortage of nirsevimab (Beyfortus™) (RSV monoclonal antibody) to protect infants and toddlers against severe RSV disease. Medical practices should prioritize limited supplies of nirsevimab to infants at highest risk of severe RSV disease until additional supply is available.

Respiratory Syncytial Virus (RSV) Webpage

Webpage includes:

- Introduction
- Prevention Tips
- Resources and Guidance
- Communication Toolkit
- Resources for Public Health
- Clinical Guidance



Calendario de la Vacuna COVID-19

Calendario de la Vacuna COVID-19 2023-24 –Calendario Rutinario			
Edad*	Vacuna	Si no está vacunado	Si recibió alguna dosis anterior, administre 2023-24 dosis:
6 meses–4 años†	Pfizer–Bebés/ Niños Pequeños	1ra Dosis → 3-8 semanas → 2da Dosis → ≥8 semanas → 3ra Dosis	Si 1 dosis previa, entonces: 3-8** semanas 1 ≥8 semanas 2 Si ≥2 dosis previas, entonces: ≥8 semanas 1
	Moderna–Pediátrico*	1ra Dosis → 4-8 semanas → 2da Dosis	Si 1 dosis previa, entonces: 4-8 semanas 1 Si ≥2 dosis anteriores entonces: ≥8 semanas 1
5–11 años	Moderna–Pediátrico*	1 Dosis	Si 1 o más dosis previas (de cualquiera de las marcas), entonces*: ≥2 meses Formulación actualizada 2023-24 Moderna/Pfizer
	Pfizer–Pediátrico	1 Dosis	
12+ años	Pfizer–Adol/Adulto (Comirnaty)	1 Dosis	
	Moderna–Adol/Adulto (Spikevax)	1 Dosis	
	Novavax	1ra Dosis → 3-8 semanas → 2da Dosis	

* Consulte las recomendaciones de los CDC para niños en transición de un grupo de edad más joven a uno mayor.
† Los niños de 6 meses a 4 años deben recibir la misma marca de vacuna actualizada que las dosis anteriores que recibieron.
** Para algunas personas, puede ser preferible un intervalo de 8 semanas, especialmente para hombres de 12 a 39 años.
≠ Todas las dosis de Moderna de 6 meses a 11 años son de 0.25 ml (25 mcg).
^ La vacuna Janssen (J & J) ha sido desautorizada. Siga el calendario de los que tienen 12+ años para cualquier dosis anterior.
[Consulte las Consideraciones Clínicas Provisionales Para el Uso de las Vacunas Contra el COVID-19](#) para obtener más detalles. El calendario esta sujeto a cambios.

California Department of Public Health, Immunization Branch IMM-1396S (10/31/23) Pagina 1 of 2

Calendario de la vacuna COVID-19 2023-24 si está moderadamente o gravemente inmunocomprometido			
Edad	Vacuna	Si no está vacunado:	Si recibió alguna dosis anterior, administre las dosis de 2023-24:
6 meses–4 años	Pfizer Bebés/ niños pequeños	1ra Dosis → 3 semanas → 2da Dosis → ≥8 semanas → 3ra Dosis → ≥2 meses → Dosis Opcional*	1 dosis previa: 3 w 1 ≥8 w 2 ≥2 dosis previa: ≥8 w 1 ≥2 m Dosis Opcional*
	Moderna–Pediátrico	1ra Dosis → 4 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → ≥2 meses → Dosis Opcional*	1 dosis previa: 4 w 1 ≥4 w 2 2 dosis previas: ≥4 w 1 ≥2 m Dosis Opcional*
5–11 años	Moderna–Pediátrico	1ra Dosis → 4 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → ≥2 meses → Dosis Opcional* Moderna/ Pfizer	≥3 dosis previas** (para mayores de 5 años, la dosis de Pfizer también está bien) ≥8 w 1 ≥2 m Dosis Opcional*
	Pfizer–Pediátrico	1ra Dosis → 3 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → ≥2 meses → Dosis Opcional* Moderna/ Pfizer	1 dosis previa: 3 w 1 ≥4 w 2 2 dosis previas: ≥4 w 1 ≥3 dosis previas** ≥8 w 1 ≥2 m Dosis Opcional*
12+ años	Pfizer–Adol/Adulto (Comirnaty)	1ra Dosis → 3 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → ≥2 meses → Dosis Opcional* Moderna/ Pfizer/ Novavax	1 dosis previa: 3 w 1 ≥4 w 2 2 dosis previas: ≥4 w 1 ≥3 dosis previas** ≥8 w 1 ≥2 m Dosis Opcional*
	Moderna–Adol/Adulto (Spikevax)	1ra Dosis → 4 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → ≥2 meses → Dosis Opcional* Moderna/ Pfizer/ Novavax	1 dosis previa: 4 w 1 ≥4 w 2 2 dosis previas: ≥4 w 1 ≥3 dosis previas** ≥8 w 1 ≥2 m Dosis Opcional*
	Novavax	1ra Dosis → 3 semanas → 2da Dosis → ≥2 meses → Dosis Opcional* Moderna/ Pfizer/ Novavax	≥1 dosis previas** ≥2 m 1 ≥2 m Dosis Opcional*
			5-11 años: Moderna/ Pfizer 12+ años: Moderna/ Pfizer/ Novavax

* Se puede administrar una dosis opcional ≥2 meses después de la última dosis. Se pueden administrar dosis adicionales a discreción del proveedor de atención médica. Consulte la [Tabla 2](#) para conocer el vial y la dosis.
** A los niños de 5 a 11 años se les puede administrar Moderna o Pfizer después de ≥3 dosis previas. A los mayores de 12 años se les puede administrar Moderna, Pfizer o Novavax.

California Department of Public Health, Immunization Branch IMM-1396S (10/31/23) Pagina 2 of 2



TOMÁS J. ARAGÓN, M.D., Dr.P.H.
Director and State Public Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

DATE: October 20, 2023

TO: California Federally Qualified Health Centers (FQHCs)

FROM: Robert Schechter, MD
Branch Chief
Immunization Branch

SUBJECT: Request for Application to assess and improve adult immunization levels in Community Health Centers: Funding for July 2023 - June 2024 for one award up to \$127,000; Applications Due 11/10/23

GRANT AGREEMENT FUNDING ANNOUNCEMENT/RELEASE

Adult immunization levels are low nationwide and in California, and disparities exist with respect to race/ethnicity, income level, and insurance coverage. Recent data suggests there are gaps in adult rates for flu, shingles, tetanus, and pneumococcal vaccines. ([Routine Vaccinations: Adult Rates Vary by Vaccine Type and Other Factors | U.S. GAO](#)). The Centers for Disease Control and Prevention (CDC) is urging providers to maintain routine immunization services for adults. Efforts to improve adult vaccinations could include expanding the number of vaccines offered, raising public and provider awareness, partnering with organizations to encourage vaccination and offering free routine vaccines to certain adults. Maintaining adult immunization rates can prevent infectious disease outbreaks and also prevent long-term illness, hospitalization, and even death from vaccine-preventable diseases.

The California Department of Public Health (CDPH) Immunization Branch has been awarded a supplemental grant to assess and improve adult immunization rates in Community Health Centers (CHCs). CDPH is seeking a large Federally Qualified Health Center (FQHC) to assess immunization levels and implement quality improvement activities to strengthen immunization practices in an identified adult patient population. FQHCs will select a vaccination to focus on and will identify a specific adult patient population of focus based on local priorities with accompanying justification. Staff from the CDPH immunization branch will provide support and technical assistance to the selected grantee.

The grant term is 7/01/2023 (or upon approval) to 6/30/2024.

CDPH has authority to grant funds for the Project under Health and Safety Code, Section 120440 (C): to compile and disseminate statistical information of immunization status on groups of patients or clients or populations in California, without identifying information for these patients or clients included in these groups or populations.

Immunization Branch / Division of Communicable Disease Control
850 Marina Bay Parkway, Bldg. P, 2nd Floor, Richmond, CA 94804
(510) 620-3737 • FAX (510) 620-3774 • Internet Address: www.getimmunizedca.org



Request for Application (RFA) to assess and improve adult immunization levels in Community Health Centers

Funding for July 2023 - June 2024 for one award up to \$127,000

Applications Due: Friday, 11/10/23

COVID-19 Vaccine Administration Data

Hailey Maeda, CDPH


COVID-19 Vaccine Administration Summary

as of October 30, 2023

92,417,380

Total Doses Administered:


Daily Doses Administered: **Statewide**



2,524,339

Total Up-to-Date* Recipients:

Percent of Population Who Are Up-to-Date



6.3%

Statewide

Percent of People Who Are Up-to-Date

1.1% 15.4%

*Has received a dose of the Updated 2023-2024 vaccine or a bivalent dose within the past 2 months

Trends in COVID-19 Vaccine Administration

as of October 30, 2023

Most Recent Eligibility Groups

- Updated 2023-2024 vaccine for 6 months and older


FDA NEWS RELEASE

FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

[f Share](#) [t Tweet](#) [in LinkedIn](#) [✉ Email](#) [🖨 Print](#)

For Immediate Release: September 11, 2023


Doses Administered by Age Group, Past 4 Weeks



COVID-19 Vaccine Up-to-Date Status by Race/Ethnicity*

as of October 30, 2023

Race/Ethnicity: % of Population by Vaccine Status:
Up To Date | Received Bivalent but Not Up to Date | Any Shot but Not Up To Date | No Shots



Highest uptake in Asian and White

Over half of those in each race/ethnicity group have received a shot but are not Up-to-Date


*Vaccination rate estimates for some groups, such as NHPI, may be affected by differences in how demographic data is collected by the Census and at the time of vaccination

COVID-19 Vaccine Up-to-Date of 65+ by County

as of October 30, 2023

By geography and age:

Uptake varies geographically
Ranges from **3.9%-34.4%** of
county's 65+ population



Updated 2023-2024 COVID-19 Doses by Provider

as of October 30, 2023

Number of Updated 2023-2024 Dose Providers vs Bivalent Dose Providers


By provider:

4,126

Total Updated 2023-2024 Dose Providers
Reported

61% of previous Bivalent
vaccine Providers

+4% pt increase from last week



Updated 2023-2024 COVID-19 Doses by Provider

as of October 30, 2023

By dose and provider:

Administration type varies by vaccine


53% of Bivalent doses

VS

61% of Updated 2023-2024 doses administered by pharmacies

% of Total of Bivalent Doses vs % of Total of Updated 2023-2024 Doses by Provider Type:

Pharmacy | Healthcare | Public Health | Other



COVID-19 Vaccine Data Summary

as of October 30, 2023

Key Metrics

92.4 million doses administered | **+443K** doses administered
6.3% Statewide who are Up-to-Date | **2.5 million** Up-to-Date recipients
7% pt difference in Up-to-Date across race/ethnic groups

System Notes

- Public dashboard Up-to-Date status now **includes** the Updated 2023-2024 guidelines
 - Public dashboard updated monthly – LHJ Dashboard updated daily
- Email cdphvaccinedatateam@cdph.ca.gov for questions and comments

Clinical Update

Caterina Liu, M.D., CDPH

Advisory Committee on Immunization Practices (ACIP)

COVID-19 Vaccine Updates

COVID-19 vaccine implementation review

- Commercialization and Bridge Access Program (BAP)
- COVID-19 vaccine coverage data and survey results

COVID-19 vaccine policy

- Review of current vaccine guidance – [Use of COVID-19 Vaccines](#)
- Future considerations include:
 - Additional vaccine doses for older adults
 - Future vaccine formula updates
 - As needed recommendation update based on ongoing surveillance of VE, safety, and epidemiology

Increased Flexibility for Interchangeability of COVID-19 Vaccines

Updated language:

In the following **circumstances**, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered:

- Same vaccine not available **at the vaccination site at the time of the clinic visit**
- Previous dose unknown
- Person would otherwise not **receive a recommended vaccine dose**
- Person starts but unable to complete a vaccination series with the same vaccine due to a contraindication

COVID-19 Vaccine Age Transition Guidance Update

- CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination ([Table 1](#) and [Table 2](#)).
- If a person moves to an older age group between vaccine doses, they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- However, for children who transition from age 4 years to age 5 years and children who are moderately or severely immunocompromised and transition from age 11 years to age 12 years, **FDA authorization allows for an alternative dosage** (see [Table 1](#) and [Table 2](#)).

Vaccine Safety – COVID-19 and Flu Vaccines

- Summary and interpretation of analyses of ischemic stroke and bivalent mRNA COVID-19 and influenza vaccination
 - Inconsistent results, most studies found no association
 - The benefits of vaccination still far outweigh the risks, especially in older adults
 - COVID-19 and influenza disease are associated with an increased risk of stroke
- Next steps
 - CDC will conduct additional analyses and continue safety monitoring
 - No changes to CDC guidance on coadministration of COVID-19 and influenza vaccines.
 - Get vaccinated to protect against the clear risks from COVID-19 and influenza this winter.

Other ACIP Topics

- Influenza vaccine
 - Safety with co-administration with mRNA COVID-19 vaccines and Zoster vaccine
 - Safety of vaccination in pregnant person, effectiveness against flu-associated hospitalizations and ED visits in infants
- Pentavalent Meningococcal vaccine now recommended; formal guidance and updated materials are coming soon.
 - Pfizer's pentavalent MenABCWY vaccine (Penbraya™) now licensed and recommended as an option when both MenACWY and MenB vaccines are indicated at the same visit.
 - Product included in the Vaccines For Children Program.
- New adult pneumococcal vaccines under late stage of development
- Chikungunya vaccine under consideration by FDA, not yet licensed


Other ACIP Topics

- RSV Vaccines for Older Adults
 - Review of epidemiology of RSV in adults
 - GSK safety and immunogenicity in persons 50-59 years of age
 - Future work group discussion: RSV vaccine is not currently approved for ages 50-59 years.
If approved, future discussion about guidance anticipated.
- 2024 Combined Immunization Schedules Approved
 - Updates to tables and notes that includes addition of new vaccines (e.g. mpox and RSV vaccines).
 - Addition of an “Addendum” page to allow for timely posting of new recommendations that occur during the year.

California Health Alert Network (CAHAN): Early RSV Activity and Use of RSV Prevention Products













- During the week ending October 21, 2023, 7.4% of respiratory specimens from sentinel laboratories in California tested positive for RSV, indicating an early start to the RSV season; in pre-pandemic years, this level of activity was generally seen in November or December.
- Nirsevimab (Beyfortus™), recommended as passive immunization to protect infants, is currently in extremely short supply, as described in the October 23, 2023, CDC [health advisory and prioritization guidance](#).
- [Maternal RSV vaccine](#) (Abrysvo™) from 32 to 36 weeks gestational age is an alternative to nirsevimab for protecting infants against severe RSV disease.

Percentage of RSV detections at clinical sentinel laboratories – California, 2018-2023 (as of October 21, 2023)



Note: Data have been shifted so that Week 1 aligns across seasons.

CDC Clinician Outreach and Communication Activity (COCA) Call: Protecting Infants from Respiratory Syncytial Virus

	Who	What	When	Where	Why	
Maternal RSV Immunization	 Pregnant people	 Pfizer RSV vaccine (Abrysvo)	 32 through end of 36 th week	 September-January*	 Primarily outpatient clinics and pharmacies	 Protects infants from severe RSV from birth through first months of life
Nirsevimab	 See Health Advisory for priority groups in the setting of limited nirsevimab during 2023-2024 season	 Nirsevimab (Beyfortus) monoclonal antibody	 First week of life, or as entering RSV season	 October-March*	 Primarily birthing hospital and outpatient clinics	 Protects infants and young children from severe RSV in the months after immunization

V-safe for RSV Vaccines in Older Adults Now Available

- V-safe now available for adults 60 years and older who received RSV vaccine
 - Will be available soon to pregnant people who received RSV vaccine
- V-safe is a safety monitoring system that lets you share with CDC how you, or your dependent, feel after getting an RSV vaccine.
- Using V-safe after RSV vaccination requires a new registration.
- Please encourage your patients to participate.



What is V-safe?

V-safe is an innovative vaccine safety monitoring system that allows you or your dependent to quickly and easily share how you feel after getting a vaccine. It takes just a few minutes to enroll, and then you will receive V-safe notifications through text messages or emails to complete **short, confidential health check-ins**. Your participation in V-safe makes a difference—it helps others know what to expect in the days following vaccination, and it helps CDC monitor the safety of vaccines for everyone.

V-safe features:

- Receive health check-ins via text or email after vaccination.
- Enroll your dependents and complete check-ins on their behalf.
- Share how you feel after getting a vaccine dose.

How can I enroll, and how does it work?

V-safe is available for several vaccines. Go to vsafe.cdc.gov to find out if you are eligible to enroll. If you are eligible, follow the prompts to register for V-safe health check-ins. During the first week after vaccination, V-safe will send you a text message or email notification each day to ask how you are feeling. Then you will get check-in messages once a week for up to 5 weeks. Depending on your answers, V-safe may send you a link to submit a report in the Vaccine Adverse Event Reporting System (VAERS).

You can opt out at any time by texting "STOP" when V-safe sends you a text message or by clicking "unsubscribe" when V-safe sends you an email. You can also opt back in by changing your preferred method of contact, found in your user profile. **Your personal information in V-safe is protected so that it stays confidential and private.***

How can I enroll my dependent?

To enroll a dependent in V-safe, add them to your existing account, or create a new account if you don't have one yet. Enrolling a dependent does not require you to enter your own vaccination information or complete health check-ins for yourself.

Need step-by-step instructions? Go to: www.cdc.gov/vsafe

Need help with V-safe?

Call 1-833-748-1979

Email VAERS.InfoDesk@hhs.gov

Visit www.cdc.gov/vsafe

QR Code: Aim your smartphone's camera at this code

CDC Logo

*V-safe follows data handling and security measures appropriate for the data's level of sensitivity. These measures comply, where applicable, with the following federal laws including the Privacy Act of 1974, standards enacted that are consistent with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the Federal Information Security Management Act, and the Freedom of Information Act.

CS-104761-V 10/06/2021

Respiratory Virus Resources

CDC COCA Call: Protecting Infants from Respiratory Syncytial Virus (RSV)

Thursday, October 26, 2023. [Webcast Recording and Slides Available Here](#)

State Public Health Leader Encourages Vaccination and Outlines Simple Steps to Stay Healthy this Winter

Friday, October 27, 2023. [Media Briefing Recording](#)


Helpful Links

- [CDC Health Advisory, October 23, 2023, Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus \(RSV\) during the 2023–2024 Respiratory Virus Season](#)
- [AAP Respiratory Syncytial Virus \(RSV\) Prevention Page](#)
- [The American College of Obstetricians and Gynecologists \(ACOG\) Maternal Respiratory Syncytial Virus Vaccination Practice Advisory](#)
- [CDC RSV Immunizations Overview](#)
- [CDC RSV Immunization for Infants and Young Children](#)
- [CDC RSV Vaccine for Pregnant People](#)

Respiratory Syncytial Virus


Christina Sapad, CDPH

Beyfortus™ Supply & Ordering Update - VFC

- Due to supply limitations nationwide, nirsevimab (Beyfortus™) was temporarily paused from VFC ordering on October 16.
-  • With the arrival of a very limited number of doses at CDC's VFC distributor, CDC has implemented allocations to states. Allocations from CDC is expected to be replenished every 2 to 3 weeks, and as product is made available by the manufacturer.
- CDPH has received a limited number of Beyfortus™ doses expected to support ordering for the next 2-3 weeks:
 - 50mg (0.5 mL) dose formulation: **6,430 doses**
 - 100mg (1 mL) dose formulation: **6,060 doses**

Beyfortus™ VFC Ordering Update

- The VFC Program has now opened ordering for nirsevimab (Beyfortus™) in MyVFCvaccines but only for a limited number of VFC Providers, including hospitals, Tribal Health Clinics, select Federally Qualified Health Centers (FQHCs)/Rural Health Centers (RHCs) and Public Health Department Clinics.
- Additional doses will be made available to additional VFC Providers as more doses are received.
- Ordering limits are based on monthly order averages of hepatitis B doses for hospitals, and PCV for outpatient providers. Maximum amounts providers may request will be indicated as part of the ordering process and the limits may be changed depending on supply.



CA VFC Program's No Borrowing Policy

- The California Vaccines for Children (VFC) Program has a no borrowing policy.
- Although earlier this fall CDC allowed states to determine the feasibility of implementing borrowing, CDC now acknowledges that borrowing and replacing doses is not feasible during the shortage.
- Given that VFC supply is allocated, doses of nirsevimab (Beyfortus™) ordered through the VFC Program **must be administered to VFC eligible patients only. Borrowing is not allowed.**


VFC Pediatric RSV Inventory Requirement

- According to VFC Program Participation requirements, VFC providers are required to maintain an inventory of both VFC and privately purchased immunizations based on the populations served and as reflected in the Provider's VFC Population Profile.
- Given the current supply limitations which continue to evolve, CDC recognizes that some VFC providers may be challenged to maintain private stock of nirsevimab (Beyfortus™) during the 2023-2024 respiratory virus season.
- As a result, the VFC Program is temporarily suspending the requirement to stock private supply of nirsevimab (Beyfortus™) for providers that serve privately insured patients. This requirement will go back into effect August 1, 2024.

Pharmacy Long-term Care Facilities (LTCF)

Edward Salaguinto, PharmD, RPh, CDPH

Find Bridge Access Program (BAP) Pharmacies



- ❖ Actively working with federal partners on LTC facility needs for staff members.
- ❖ Identified all pharmacies that either have their primary or secondary focus on LTCFs
- ❖ Some of the pharmacies on the list are Retail and LTC pharmacies
- ❖ Some are considered 'closed door' and only support facilities without offering any retail operations.

To register, visit:
www.joinetrueenorth.com



The Bridge Access Program is funded by the U.S. Department of Health and Human Services and the Center for Disease Control and Prevention.

All pharmacy applications are subject to approval by HHS.

Bridge Access Program

eTrueNorth, in partnership with HHS,* is helping expand free COVID-19 vaccine access in communities across the U.S.

Through the Bridge Access Program, pharmacies enrolled with eTrueNorth can receive reimbursement for administering no-cost COVID-19 vaccines to uninsured and underinsured adults.



By encouraging enrollment, you can:



Help pharmacies **expand access to the underserved** members of your community.



Streamline **access to reimbursement** for vaccinations administered to the **uninsured** population.



Support more **robust IIS reporting**.

Sunsetting the US Government Distribution of COVID-19 Therapeutics: Reminders

Projected Timeline (All subject to change)	Action/Event	Product
10/2/2023	HHS switched Lagevrio threshold/replenishment to a request-based approach using an out-of-cycle (OOC) process	Lagevrio
11/1/2023	Commercial Lagevrio launch by Merck (unique NDC relative to USG-procured supply). Lagevrio available for purchase.	Lagevrio
11/1/2023	Commercial Paxlovid launch by Pfizer (NDA-labeled, unique NDC relative to EUA-labeled USG-procured supply. Paxlovid available for purchase).	Paxlovid
11/10/2023, 12:00PM PT	Last day for awardees to submit orders for Lagevrio USG product (federal entities, excluding DoD and VA, can continue to order USG supply)	Lagevrio
11/27/2023	HHS switch from the Paxlovid threshold/replenishment to a request-based approach using an OOC request process.	Paxlovid
12/15/2023, 12:00PM PT	Last day for awardees to submit orders for Paxlovid USG product (federal entities can continue to order USG supply)	Paxlovid
11/15/2023 - 12/31/2023	Providers with excess USG-distributed, EUA-labeled Paxlovid are encouraged to return product through the Pfizer returns process to facilitate a credit to USG. Recommendation: Please consider to process returns in December to allow time to secure NDA-labeled inventory	Paxlovid

Programs for Uninsured and Underinsured Individuals

Product	Programs	Description and additional information
Lagevrio	Patient Assistance Program Bulk Replacement Program	Information available November 1, 2023 Website: merckhelps.com Tel: 800-727-5400
Paxlovid	Available November 1, 2023: Co-pay Savings Program by Pfizer	Information available November 1, 2023 Co-pay savings program will be available for eligible commercially insured patients
Paxlovid	Available ~December 1, 2023: Patient Assistance Program using USG supply	Information available ~December 1, 2023 Website: For Patients https://www.paxlovid.com/ Tel: 1-877-219-7225 (1-877-C19-PACK)

Note: Select pharmacies will be able to process manufacturers' patient assistance programs. More details coming soon.

COVID-19 Vaccine Quality Assurance

CAIR/RIDE Registry ID and Demonstration

Kelley Leung, RN, CDPH

CAIR/RIDE Registry ID's

Under AB 1797, vaccine providers are required to enter immunization information into the California Immunization Registry ([CAIR](#)) OR [Healthy Futures/RIDE](#).

119 VFC Providers have no IIS Org Code.

Reminder to Providers: Please join CAIR/RIDE.



COVID-19 Vaccine Storage Demonstration



Correct Dosing Information: Moderna Vaccine

- The single dose vial (SDV) of Moderna COVID-19 Vaccine (2023-2024 Formula) for children 6 months through 11 years of age contains, notably, more than 0.25 mL dose.
- Do not withdraw the entire contents of the vial.
- Please ensure staff are educated on the correct dose volume (0.25 mL).
- Vials must be discarded after withdrawal of one dose.

[Important Information About the Correct Dosage and Administration of Moderna COVID-19 Vaccine \(2023-2024 Formula\) for Individuals 6 Months Through 11 Years of Age | FDA](#)

CDPH COVID-19 Testing Updates

Stefanie Medlin, MPH, Medical Countermeasures Unit, CDPH



California Healthcare Centers, Clinics and Pharmacies

Request COVID-19 At-home Tests!

- One-time distribution in preparation for the respiratory viral season
- Tests are for uninsured, underinsured, Medicare recipients, or at high risk of severe disease.
- COVID-19 tests must be provided for free.
- Your organization CANNOT bill patients' insurance for the tests.
- At-home tests are self-tests; they must be distributed to the individual and performed by the individual (or their parent/guardian).

At-home Test Ordering Information

- Tests expire December 2023 (extended expiration)
- Use this link to place an order for up to a 2-month supply of tests before **November 30, 2023**:
<https://labsupport.powerappsportals.us/ordercovidotc/> *
- Tests must be stored INDOORS, in a temperature-controlled space [less than 86 degrees] as soon as they are delivered.
- A case of 180 tests is 12" L x 13" W x 11" H.
- A pallet of 15,120 tests is 4 ft x 4 ft x 6 ft.

* Tests are to be ordered directly by the health care center, clinic, or pharmacy. Order form should NOT be shared with the public.


Free COVID-19 At-home Tests: Please Share

- All [insured](#) people can request 8 free (or reimbursed) tests each month from pharmacies or retail stores through Saturday, November 11, 2023.
- Learn more at [How to Get Testing CA All](#)
- U.S. households can order 4 more free COVID-19 rapid tests:
<https://www.covid.gov/tests>
- [Home Test to Treat](#) is a federal program that offers free tests and free treatment (if eligible) for COVID-19 at home 24/7. No insurance or appointments needed!
- For more information on the changes to COVID-19 Medical Coverage [COVID-19 Medical Coverage Changes](#)

Extended Expiration Dates on At-home Tests

- Most printed expiration dates are not correct and have been extended.
- Check to see the correct expiration date on the [FDA website](#).
- Replace tests that are older than the **extended** expiration dates.
- If newer tests are not easily available, you may use an expired test as long as the internal control line remains valid.


COVID-19 Treatments Resources & Toolkits



POSITIVE FOR COVID-19?
TREAT IT!
GETTING TREATMENT EARLY
CAN MAKE A BIG DIFFERENCE

- 1 Feeling sick?
Get tested.
- 2 Tested positive?
Ask about COVID
medication.
- 3 Call your doctor, urgent care, or the state COVID-19
hotline at **833-422-4255** and ask about the
COVID-19 medications.


Learn more at: covid19.ca.gov/treatment
Source: California Department of Public Health



¿TIENES COVID-19?
¡TOMA LA PASTILLA!
TRATARLO DE FORMA TEMPRANA
PUEDE MARCAR UNA GRAN DIFERENCIA

- 1 ¿Te sientes mal?
Hazte la prueba.
- 2 ¿Salió positiva?
Consulta por
medicación para el
COVID.
- 3 Llama a tu médico, centro de atención de
emergencia o a la línea directa
estatal para COVID-19 al **833-422-4255** y
consulta por medicación para el COVID-19.

Obtén más información en
covid19.ca.gov/treatment
Fuente: Departamento de Salud Pública de California



Providers can access additional shared resources on treatment by accessing the [CDPH COVID-19 Treatments Toolkit](#).

For questions, please contact OTCTesting@cdph.ca.gov

Vaccine Management

Josh Pocus, My Turn, and Maria Volk, myCAvax

What's New in My Turn? – Release 44 (1 of 3)



New updates for Patients launched on
Thursday, November 2, 2023!

Release Highlights




Patients will now be able to:

- ✓ Only view the vaccine brand for the vaccine tags on the 'Select a Location' page
- ✓ View an updated description text below the 'Vaccine Brand' header and the numbers added next to each step on the 'Select date & time' page
- ✓ View the new 'Other' option in the dropdown of the 'Primary carrier' question that opens up a text field when selected
- ✓ View the refreshed look and feel of the My Turn Public portal
- ✓ View the 'Pfizer - All doses' and 'Moderna - All doses' tag on the 'Walk-in' page if all doses are offered
- ✓ View the new 'Can I mix and match COVID-19 vaccine brands?' question added to the 'Q&A' section
- ✓ View a new note added in the 'Health Insurance' section about the patient's insurance information that will be verified at the time of their appointment
- ✓ View an updated footer on the My Turn Public portal that includes a link to report any issue

Patients will no longer be able to:

- ✓ View the health insurance description text on the clinic cards if the 'Privately funded' vaccine supply is removed from the clinic

My Turn Public



What's New in My Turn? – Release 44 (2 of 3)



New updates for Clinic Managers, Vaccine Administrators, and new My Turn users launched on **Thursday, November 2, 2023!**

Release Highlights



Clinic Managers and Vaccine Administrators will be able to:

- ✓ View the updated COVID-19 timing chart hyperlink within the attestation under the 'Patient Background' field while on the VA and IIS flows, and under the 'Vaccine Brand' field while single editing an appointment and on the Walk-in flow
- ✓ View the updated 'Uninsured status confirmed?' checkbox attestation under the 'Health Insurance' section if they select 'No' in response to the question 'Does the patient have health insurance?' on the Walk-in flow

Clinic Managers and Vaccine Administrators will no longer be able to:

- ✓ View the 'Vaccine Supply' section while viewing / editing clinic details
- ✓ View a tooltip on the 'End Date' field
- ✓ View the health insurance description text on clinic cards if the 'Privately funded' vaccine supply is removed

New My Turn users will be able to:

- ✓ Receive an automated confirmation email for their application submission, approval, or rejection with the updated Help Desk email and hours of operation
- ✓ View the updated Help Desk email and hours of operation in an error message while adding a new Provider Location on the unauthenticated Digital Enrollment flow

Clinic Managers and myCAvax users will no longer be able to:

- ✓ View the 'Delivery Instructions' field on the 'Provider Location Information' page
- ✓ View the fields required for Provider of Record Title and Provider of Record Medical License Number

What's New in My Turn? – Release 44 (3 of 3)



New updates for Clinic Managers and myCAvax users launched on
Thursday, November 2, 2023!


Release Highlights



Clinic Managers and myCAvax users will be able to:


- ✓ Search for an existing user on the 'Provider of Record' field that will filter for contacts with only CEO / CMO / POR titles
- ✓ Input an existing location and edit missing fields while on the authenticated Digital Enrollment flow
- ✓ View the character limit for input in any 'Name' or 'Email' fields, matching the myCAvax Digital Enrollment flow
- ✓ View a new field labeled "Please specify 'Other' Provider Type" in Step 2 of the enrollment if 'Other' is selected as the provider type option
- ✓ View the updated Help Desk email and hours of operation when entering duplicate IIS numbers on the IIS information page and on both the new and existing Provider Location flows for locations associated with the My Turn program

My Turn Clinic



My Turn Public Site Refresh: Landing Page and Navigation

The My Turn Public portal will be revamped with a refreshed appearance and user experience, designed to ensure it is more accessible, user-friendly, aesthetically pleasing, and efficient for patients while booking appointments.



My Turn Clinic Setup

Clinic Managers can set up a new clinic by entering all the details, including the Name, Address, Provider Location associated with the clinic, operating days, and availability. For allowing patients to book appointments at the clinic, the Clinic Manager must activate the clinic location.

1

0% Complete

STEP 1
Set up your clinic

Set clinic visibility
Choose whether you want to allow your clinic on My Turn Public. If you select 'No' your clinic will only support walk-in patients until you change this setting.

Allow Clinic on My Turn ☐ Yes ☒ No

Clinic name and location
We recommend keeping your clinic's public-facing name (what appears on My Turn) to the name/location. To differentiate clinics internally, add more detail to the internal clinic name, such as vaccine type, brand, or dose.

Internal Clinic Name
Vaccine - Sacramento - COVID - 2 dose

Phone Number
(916) 473-8553

Provide the address where your clinic will be administering vaccines.

Address
Street
3420 China Hall Road NW

City
Sacramento

State/Province
CA

Zip/Postal Code
95829

Country
US

2

50% Complete

STEP 2
Clinic operations

Set the first day your clinic would like to start scheduling patient appointments. This date will control when the public can see your clinic on My Turn, and start scheduling the appointments ahead of the clinic opening.

Available date
Oct 26, 2023

How long will your clinic be open? Your start date and end date control which dates show as available for appointments in the system.

Start date
Oct 26, 2023

End date
Nov 10, 2023

Will your clinic use a third-party site to manage appointment scheduling?
Use Third-Party website for appointment scheduling ☐ Yes ☒ No

3

90% Complete

STEP 3
Clinic Availability

Final steps for setup
In order to complete your clinic setup, you must enter your clinic's vaccine inventory. Please follow the steps outlined below:

1. Navigate to Vaccine - Sacramento - COVID - 2 dose
2. Click on Availability to set up the days and hours of operation
3. Click on the vaccine inventory tab and ensure all vaccine types are added to the system and their status is set to 'available'

Once your inventory is in place, your clinic setup is complete.

Create

Clinic
Sansa's Clinic

Book Appointments

Activate Location ☒

Details Vaccine Inventory Vaccine Supply **Availability** SMS Requests Tag Reporting Contacts Clinic Links

Need Help? Please see the [Add Availability](#) job aid.

Day	Opening hours	Time window duration (mins)	Appointments per time window	Total appointments
<input checked="" type="checkbox"/> MON	09:30 AM - 05:00 PM <input type="checkbox"/> All day	360	100	100
<input checked="" type="checkbox"/> TUE	09:30 AM - 05:00 PM <input type="checkbox"/> All day	360	100	100
<input checked="" type="checkbox"/> WED	09:30 AM - 05:00 PM <input type="checkbox"/> All day	360	100	100
<input checked="" type="checkbox"/> THU	09:30 AM - 05:00 PM <input type="checkbox"/> All day	360	100	100
<input checked="" type="checkbox"/> FRI	09:30 AM - 05:00 PM <input type="checkbox"/> All day	360	100	100
<input checked="" type="checkbox"/> SAT	09:30 AM - 05:00 PM <input type="checkbox"/> All day	360	100	100

Upcoming My Turn Public Maintenance



My Turn Public users may experience a temporary degradation of service due to security maintenance on **Tuesday, November 7, 2023**, from **4:00 PM – 5:00 PM PT**.



Bridge Access Program (BAP): Program Eligibility and Completing BAP Enrollment

If you do not see the enrollment pop-up window, contact the Provider Call Center to confirm your Contact has the appropriate Program Role. Only Organization Vaccine Coordinators and Primary Vaccine Coordinators for BAP will be able to enroll their locations.

Providers serving uninsured / underinsured adults through Public Health Departments, Federally Qualified Health Centers (FQHCs) / Rural Health Centers, Tribal Clinics, and Indian Health Services sites are eligible for BAP.

Questions about BAP enrollment? Contact the Provider Call Center at providercallcenter@cdph.ca.gov or call (833) 502-1245, M–F 8:00 AM – 5:00 PM PT.



BAP: Vaccine Allocations Cadence Update




CDPH uploaded additional allocations for Pfizer and Moderna COVID-19 vaccines on **Friday, October 27, 2023**. Biweekly allocation refreshes are starting this week for all products.

CDPH also received an initial allocation from CDC on **Tuesday, October 10, 2023**, for the updated Novavax vaccine.

BAP: Provider Enrollment Update

Great work! **68%** of BAP-eligible providers have enrolled in the program so far.

As of **Tuesday, October 24, 2023**, **796** BAP-eligible providers have completed enrollment, out of **1166** total providers eligible for BAP enrollment.



The BAP enrollment deadline for providers passed on **Friday, October 27, 2023**. Providers can still complete BAP enrollment until **Monday, November 6, 2023**, in myCAvax. All Provider Locations not enrolled by this date will have their program status listed as 'inactive'.




If an active BAP-eligible provider would like to disenroll from BAP, they will need to reach out to their LHD and disclose their reasoning to begin the disenrollment process.

All Future Program Provider Contact Changes / Updates



Vaccine Coordinators are now approved to authorize contact changes for other coordinators on their parent account. After the program provider contact change is requested, the Provider Call Center will note via Chatter who requested the contact change.

Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

My Turn – Known Issues and Workarounds



Known Issues

Patients Not Receiving SMS and Email Notifications when Appointment is Rescheduled

- ✓ We are tracking an issue where patients are not receiving SMS and / or email notifications when the clinic reschedules their appointments.

Missing My Turn Program

- ✓ We are tracking an issue where some locations that were participating in My Turn prior to the rollout of Digital Enrollment on **August 30, 2023**, are missing the My Turn program.
- ✓ Affected users will see an error message on their 'Clinics' page saying "The selected location is not currently active. You may view historical clinics; new clinics cannot be created."

Unable to Archive some Vaccine Inventory Records

- ✓ We are working on a fix for an issue where providers are unable to archive Vaccine Inventory records for some of the products that were recently deauthorized.



Workaround / Next Steps

- ✓ Estimated Fix: **November 2, 2023**
- ✓ Estimated Fix: **November 2, 2023**
- ✓ Workaround: Reach out to the Provider Call Center.
- ✓ Estimated Fix: **November 2, 2023**

myCAvax – Known Issues and Workarounds



Known Issues

'Physician's Assistant' License Type on SGF Enrollment Leading to Endless Spinner

- ✓ For LHD users still completing their SGF enrollment, if you add a Provider of Record with a license type of 'Physician's Assistant,' you will be met with an endless spinner when trying to complete your enrollment.

Fluarix Shipment Not Showing the Correct Product

- ✓ It has been reported that for some orders of ADU Fluarix the shipment is showing as PED Fluarix and vice versa. In addition to fixing the logic, we will also clean up previously affected shipments.



Workaround / Next Steps

- ✓ Estimated Fix: **November 2, 2023**
 - ✓ Workaround: Use the 'Other' license type instead of 'Physician's Assistant' and leave a chatter note on the 'Program Location Application' record to let the Enrollment team know that your Provider of Record is a Physician's Assistant.
-
- ✓ Estimated Fix: **November 9, 2023**
 - ✓ For the time being, refer to the order for the source of truth and ignore the product listed on the shipment.

Resources and Q&A

Leslie Amani, CDPH

Vaccine Support


Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.  Need help? View our jobs aids in the Knowledge Center, or contact us.



COVID-19 Therapeutics Resources

Type of Support


Description

Updated 10.6.23



Clinical Guidance

For general Therapeutics questions, please email: COVIDRxProviders@cdph.ca.gov



General Information

[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)

[CDPH COVID-19 Treatments Job Aid](#) (questions and answers for the public on COVID-19 therapeutics)

[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more)


[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (arcgis.com)
- [Test-to-Treat](#) (hhs.gov)



[LHJ Therapeutics SharePoint](#)

Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email JEOCuser54@cdph.ca.gov)

- [Therapeutic Weekly Email Update](#) files (SharePoint)
- [CDPH Therapeutics HPoP Account Verification & Reporting](#) information



Questions


For general CDPH Therapeutics questions, please email COVIDRxProviders@cdph.ca.gov

For ordering, program inquiries, signing up new HPOP Accounts: please e-mail CDPHTherapeutics@cdph.ca.gov

How to Pay for Vaccines


New CDC resource covers:

- Private Insurance
- Medicare
- Medicaid
- Military
- No Insurance (for adults and children)



CA DMHC Resource in English and Spanish

KNOW YOUR HEALTH CARE RIGHTS



COVID-19 Tests, Vaccines & Treatment

Health Plan Enrollees Have the Right to COVID-19 Tests, Vaccines and Treatment with No Cost-Sharing

Health plans¹ regulated by the California Department of Managed Health Care (DMHC) must cover COVID-19 tests, vaccines and treatment² with no health plan prior authorization or enrollee cost-sharing. Enrollee cost-sharing includes co-pays, co-insurance, deductibles or other enrollee out-of-pocket costs not including health plan premiums.

Continued Access to COVID-19 Tests, Vaccines and Treatment with No Cost-Sharing

California state laws add six months to the federal COVID-19 public health emergency requirements on health plans to continue covering COVID-19 tests, vaccines and treatment from any licensed provider (in- or out-of-network) with no prior authorization or enrollee cost sharing. The public health emergency ends on May 11, 2023, and state laws extend these requirements for six months through November 11, 2023.

After November 11, 2023, enrollees can continue to access COVID-19 tests, vaccines and treatment with no prior authorization or cost sharing when they access these services through their health plan's network. Health plan enrollees can be charged cost-sharing only if these services are provided out of network after November 11, 2023.

Did You Know?

Health plan enrollees have the right to eight free over-the-counter at-home COVID-19 tests a month. Health plans must continue to cover the same number of at-home tests after the public health emergency. Contact your health plan for details.

Need Help?

Contact the DMHC Help Center at www.HealthHelp.ca.gov or 1-888-466-2219. You can also find more information and resources at www.covid19.ca.gov.

¹ Commercial and Medi-Cal managed care plans regulated by the DMHC.

² Treatment means therapeutics approved or granted emergency use authorization by the federal Food and Drug Administration for treatment of COVID-19 when prescribed or furnished by a licensed health care provider acting within their scope of practice and the standard of care (HSC Section 1342.2 (h)(1)).


980 9th Street, Suite 500
Sacramento, CA 95814

Visit HealthHelp.ca.gov to submit a complaint form online or call 1-888-466-2219





CONOZCA SUS DERECHOS DE ATENCIÓN MÉDICA



Pruebas, vacunas y tratamiento del COVID-19

Los afiliados al plan de salud tienen derecho a recibir pruebas, vacunas y tratamiento del COVID-19 sin costos compartidos

Los planes de salud¹ regulados por el Department of Managed Health Care de California deben cubrir las pruebas, las vacunas y los tratamientos del COVID-19² sin autorización previa del plan de salud sin costos compartidos para el afiliado. Los costos compartidos del afiliado incluyen copagos, coseguros, deducibles u otros costos de bolsillo del afiliado sin incluir las primas del plan de salud.

El acceso continuo a las pruebas, vacunas y tratamientos del COVID-19 sin costos compartidos

Las leyes estatales de California agregan seis meses a los requisitos federales de emergencia de salud pública de COVID-19 en los planes de salud para continuar cubriendo las pruebas, vacunas y tratamiento del COVID-19 de cualquier proveedor con licencia (dentro o fuera de la red) sin autorización previa ni costos compartidos del afiliado. La emergencia de salud pública finaliza el 11 de mayo de 2023, y las leyes estatales extienden estos requisitos por seis meses hasta el 11 de noviembre de 2023.

Después del 11 de noviembre de 2023, los afiliados pueden continuar accediendo a las pruebas, vacunas y tratamientos del COVID-19 sin autorización previa ni costos compartidos cuando acceden a estos servicios a través de la red de su plan de salud. A los afiliados del plan de salud se les puede cobrar el costo compartido solo si estos servicios se proporcionan fuera de la red después del 11 de noviembre de 2023.

¿Sabía que?

Los afiliados al plan de salud tienen derecho a ocho pruebas del COVID-19 gratuitas sin receta médica en el hogar al mes. Los planes de salud deben continuar cubriendo el mismo número de pruebas en el hogar después de la emergencia de salud pública. Comuníquese con su plan de salud para obtener más detalles.

¿Necesita ayuda?




Comuníquese con el Centro de Ayuda del DMHC en www.HealthHelp.ca.gov o llamando al 1-888-466-2219. También puede encontrar más información y recursos en www.covid19.ca.gov.

¹ Los planes de atención administrada comerciales y de Medi-Cal regulados por el DMHC.

² Tratamiento significa terapias aprobadas u autorizadas por la Food and Drug Administration para el tratamiento del COVID-19 cuando son indicadas o proporcionadas por un proveedor de atención médica con licencia que actúa dentro de su ámbito de práctica y el estándar de atención (Código de Salud y Seguridad de California [Health and Safety Code, HSC], Sección 1342.2 [h](1)).

980 9th Street, Suite 500
Sacramento, CA 95814

Visite HealthHelp.ca.gov para enviar un formulario de queja en línea o llame al 1-888-466-2219

EZIZ.ORG

(Easy Immunization)

Please bookmark
<https://eziz.org/>
for immunization
updates, resources,
and guidance

The screenshot shows the EZIZ.ORG website, a one-stop shop for immunization training and resources. The interface includes a top navigation bar with the EZIZ logo and a search bar. A left sidebar contains a menu with the following items: Home, Vaccine Programs, Vaccine Management, Storage Units, Temperature Monitoring, **Training & Webinars** (highlighted), Clinic Resources, and Patient Resources. The main content area is divided into several sections: California's Vaccine Programs (featuring VFC, VFA, BAP, and 317 programs), Ordering & Vaccine Management, Storage Requirements, Alerts! (featuring a 2023 COVID-19 Vaccine update and RSV resources, both highlighted), and Immunization Registry Now Required! (highlighted). A right sidebar contains Hot Topics (featuring Weekly CDPH Immunization Updates for Providers, highlighted), Popular Resources, and CDPH Applications. The bottom of the page features a footer with the CDPH logo.

EZIZ
A one-stop shop for immunization training and resources.

California's Vaccine Programs

- VFC**: California Vaccines for Children Program
- VFA**: California Vaccines for Adults Program
- BAP**: California Bridge Access Program
- 317**: Local Health Departments

Ordering & Vaccine Management

- MyVFCvaccines (for VFC and VFA)
- MyCAVax (for BAP and 317)

Storage Requirements

- Vaccine Storage Units
- Digital Data Loggers

Alerts!

2023 COVID-19 Vaccine

- CDC Recommendations Updated for Novavax 2023-24 formulation (10/6)
- COVID-19 Vaccine Resources: [For Providers](#) | [For Patients](#)
- Vaccine Ordering and Manufacturer Info

Protect your patients against RSV!

- RSV Immunization FAQs
- More RSV Resources for Providers and Patients

Immunization Registry Now Required!

AB 1797 requires California providers to enter immunizations they administer as well as a patient's race and ethnicity into a California immunization registry (CAIR or Healthy Futures/RIDE). [Enroll in CAIR today!](#) To learn more, see the [AB 1797 FAQs](#).

Hot Topics

Weekly CDPH Immunization Updates for Providers

- Timing Schedule with Blocks (Updated for RSV)
- COVID-19 Vaccine Resources

Popular Resources

- For Patients and Staff
- Flu
- Mpox
- Pertussis
- Schedules & Recommendations
- VFC Vaccine Fact Sheets
- For Pharmacies
- More Resources

CDPH Applications

- My Turn** (COVID/Flu Vaccine Administration System)
- CAIR** (California Immunization Registry)
- My DVR** (Digital Vaccine Records)
- CAIR-ME** (Medical Exemptions from Immunizations for School and Child Care)

Contact VFC

Phone: (877) 243-8832
Hours: Mon-Thurs, 9AM-4:30PM
Friday, 9AM-4PM
[Send us an email](#)
Fax: (877) 329-9832

- VFC Field Representatives
- Find VFC providers
- Sign up for EZIZ emails
- Frequently Asked Questions

Provider Operations Manual

California Bridge Access Program


Special Note for Providers

You played a critical role in helping to end the COVID-19 pandemic.

For patients, you are one of the most trusted sources of information when it comes to vaccines. Patients may have questions and concerns about COVID-19 vaccines. You can help them understand the importance of vaccination, provide your strong recommendation, and build confidence in vaccines.

Strong vaccine confidence leads to more people getting vaccinated, which leads to fewer COVID-19 illnesses, hospitalizations, and deaths.

Thank you for the efforts you and your practice staff are making to keep California healthy.





California Bridge Access Program

Provider Operations Manual

no-cost
COVID-19 vaccines

thank
you

for uninsured &
underinsured adults



California
Bridge Access
Program

[Click to Navigate](#)
Table of Contents

[Startup Guide](#)


[Appendices](#)
Important contacts

[Infrequent Tasks](#)
Introduce new vaccines, change staff or contacts, set up new storage unit, and data logger

1 Ordering Vaccines About vaccine orders Vaccine products Submitting vaccine order requests Minimizing shipment delays When to expect vaccines	2 Receiving & Storing Vaccine Shipments About receiving shipments Moderna Novavax Pfizer-BioNTech Reporting shipment incidents	3 Routine Tasks & Reporting Recurring tasks & frequency Reporting requirements Reporting temperature excursions Expiration & beyond-use dates Wastage & missed opportunities Reporting & return of nonviable doses Transferring vaccines Transferring vaccine	4 Managing Vaccine Inventory Inventory management checklist Monitoring temperatures Reporting temperature excursions Expiration & beyond-use dates Wastage & missed opportunities Reporting & return of nonviable doses Transferring vaccines Transferring vaccine	5 Patient Visit Patient visit checklist Eligibility Screening & Documentation How to Screen & Document Eligibility Vaccine preparation & administration Responding to administration errors Billing & Reimbursement
--	--	--	---	---


COVID-19 Vaccine Provider FAQs

Answers to provider questions



Q: Is the new Novavax COVID-19 vaccine available for ordering?

A: Yes. The new Novavax COVID-19 vaccine is now available for ordering. For more information, refer to the CDPH [Vaccine Ordering and Manufacturer Info](#) page.



Q: How are COVID-19 vaccines being paid for?

A: The following resources will provide details on how COVID-19 vaccines are paid for:

- [How to Pay for Vaccines \(CDC\)](#)
- [How Will I Pay for My Family's Vaccinations?](#)

COVID-19 Vaccine FAQs v.134_10.26.23 1

COVID-19 Vaccine FAQs

For providers administering COVID-19 vaccine.
Providers may also visit [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

New and Updated FAQs..... 2

COVID-19 Vaccine Access..... 2

Bridge Access Program (BAP)..... 4

Pharmacies..... 6



Vaccines For Children (VFC) 7

Vaccine Administration..... 7

Vaccine Storage & Handling..... 9

Reporting..... 10

Communication Resources 12




CDPH Provider Webinars and Trainings

Week of November 6, 2023

	Monday 11/6	Tuesday 11/7	Wednesday 11/8	Thursday 11/9	Friday 11/10
Live Webinars and Training					Veterans' Day Holiday
View On Demand	<ul style="list-style-type: none"> Intro to My Turn Onboarding (v. 1/4/22) CDPH Weekly Provider Webinars Archived Recordings and Slides 		<ul style="list-style-type: none"> myCAvax Release Notes for LHJs and CDPH Users (Requires myCAvax Login) Latest Features in myCAvax for Providers (Requires myCAvax Login) COVID-19 Crucial Conversations Archived Webinars and Slides 	<ul style="list-style-type: none"> Moderna COVID-19 Vaccine Resources for Providers CDC COVID-19 Vaccine Webinar Series California Immunization Coalition COVID Conversation Series AIM Vaccine Confidence Toolkit Webinar Series 	
Help	Help Desk myCAvax Help Desk Email: mycavax.hd@cdph.ca.gov My Turn Help Desk Email: myturn.clinic.hd@cdph.ca.gov My Turn Onboarding Email: myturnonboarding@cdph.ca.gov		General CDPH Provider Call Center: 1-833-502-1245, 8am-5pm, Mon-Fri Email: providercallcenter@cdph.ca.gov Vaccines: COVID-19 Vaccines Therapeutics: COVID-19 Therapeutics		Mpox Email: stdcb@cdph.ca.gov General Website: Mpox Website Vaccines: Mpox Vaccines Website

Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be
dropped into, “Chat”



Upcoming Webinar Opportunities

CDPH Immunization Updates for Providers

Next session: Friday, November 17, 2023

9AM – 10:30AM

Reminder:

There will be no Friday, November 10, 2023, Provider Webinar in observance of the Veterans' Day Holiday

